About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
FATE - Fate Therapeutics| Previous Close | $89.72 | Open | $92.40 |
| Volume | 588K | Market Cap | 7.527B |
| Yield | Last Dividend |
| Mizuho Securities Stick to Their Buy Rat... | 02/25/21 |
| Mizuho Securities Stick to Their Buy Rating for Fate Therapeutics | |
| Vista Partners LLC | San Diego-Based Fat... | 02/19/21 |
| San Diego-based Fate Therapeutics, Inc. (NASDAQ: FATE) has established a leadership position in the clinical development and manufacture of universal,... | |
| Critical Analysis: Fate Therapeutics (NA... | 02/08/21 |
| QIAGEN (NYSE:QGEN) and Fate Therapeutics (NASDAQ:FATE) are both medical companies, but which is the superior investment? We will contrast the two comp... | |
| Fate Therapeutics (FATE) looks headed fo... | 01/26/21 |
| Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharma company, has been drawing the market???s attention after reporting positive results... | |
| Fate Therapeutics Announces Pricing of P... | 01/06/21 |
| SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the ???Company??? or ???Fate Therapeutics???) (NASDAQ: FATE), a clinical-stage??... | |
| Fate Therapeutics Announces Proposed Pub... | 01/04/21 |
| SAN DIEGO, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the ???Company??? or ???Fate Therapeutics???) (NASDAQ: FATE), a clinical-stage??... | |
| Oppenheimer Stick to Their Buy Rating fo... | 12/07/20 |
| Oppenheimer Stick to Their Buy Rating for Fate Therapeutics | |
| The Daily Biotech Pulse: Lilly Secures A... | 12/03/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 2) Amic... | |
| The Daily Biotech Pulse: Pfizer-BioNTech... | 12/02/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 1) AbbV... | |
| The Daily Biotech Pulse: Urovant In M&A ... | 11/13/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 12) ALX... | |
| The Daily Biotech Pulse: Lilly's COVID-1... | 11/10/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 9) Alco... | |
| The Week Ahead In Biotech: Supernus, San... | 11/08/20 |
| Biotech stocks turned around with the broader market in the week ended Nov. 6, as investors warmed to the idea of a split Congress and a change of gua... | |
| Fate Therapeutics, Inc. (NASDAQ:FATE) Gi... | 10/24/20 |
| Fate Therapeutics, Inc. (NASDAQ:FATE) has received a consensus recommendation of ???Buy??? from the seventeen analysts that are currently covering the... | |
| Zacks Investment Research Downgrades Fat... | 10/23/20 |
| Fate Therapeutics (NASDAQ:FATE) was downgraded by Zacks Investment Research from a ???hold??? rating to a ???strong sell??? rating in a note issued to... | |
| Fate Therapeutics, Inc. (NASDAQ:FATE) Ge... | 10/23/20 |
| Fate Therapeutics, Inc. (NASDAQ:FATE) General Counsel Cindy Tahl sold 29,199 shares of the stock in a transaction that occurred on Friday, October 16t... | |
| Fate Therapeutics (NASDAQ:FATE) Cut to ?... | 10/22/20 |
| Fate Therapeutics (NASDAQ:FATE) was downgraded by Zacks Investment Research from a ???hold??? rating to a ???strong sell??? rating in a note issued to... | |
| Cindy Tahl Sells 29,199 Shares of Fate T... | 10/22/20 |
| Fate Therapeutics, Inc. (NASDAQ:FATE) General Counsel Cindy Tahl sold 29,199 shares of the business???s stock in a transaction that occurred on Friday... | |
| Fate Therapeutics (NASDAQ:FATE) Shares D... | 10/21/20 |
| Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) dropped 7.7% during trading on Wednesday following insider selling activity. The stock traded as low a... | |
| Fate Therapeutics (NASDAQ:FATE) Stock Pr... | 10/21/20 |
| Fate Therapeutics, Inc. (NASDAQ:FATE) shares were down 7.7% during trading on Wednesday following insider selling activity. The stock traded as low as... | |
| Insider Selling: Fate Therapeutics Inc (... | 10/20/20 |
| Fate Therapeutics Inc (NASDAQ:FATE) General Counsel Cindy Tahl sold 29,199 shares of the firm???s stock in a transaction on Friday, October 16th. The ... | |
| The Daily Biotech Pulse: J&J Pauses Coro... | 10/13/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 12) 10X... | |
| The Daily Biotech Pulse: Gilead, Lilly C... | 10/08/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-Week Highs Oct. 7) 10X ... | |
| The Daily Biotech Pulse: Bristol-Myers S... | 10/07/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 6) 10X ... | |
| T-Cell Therapy Market Explore By Size, S... | 10/01/20 |
| Reports and Data has added a new report titled Global T-Cell Therapy Market to its ever-expanding repository, which aims to offers valuable insights i... | |
| The Daily Biotech Pulse: Eton Snags Seco... | 09/30/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 29) Ac... | |
| The Daily Biotech Pulse: FDA Nod For Pfi... | 09/29/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 28) 10... | |
| The Daily Biotech Pulse: Moderna Expands... | 09/16/20 |
| Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 15) Avidity Biosciences Inc (NASDAQ: RNA ) Beigene Ltd (NASDAQ: BGNE ) Bicycle Therapeut... | |
| Fate Therapeutics Reports Second Quarter... | 08/05/20 |
| Partial Response Reported with FT596 Monotherapy at First Dose Level in Refractory DLBCL Patient Enrollment Initiated with FT596 in Combination with??... | |
| The FLAG Award For Teaching Excellence A... | 07/29/20 |
| NEW YORK, July 29, 2020 /PRNewswire/ -- The FLAG Award for Teaching Excellence (FATE) announces Dr. Lou Lahana as the winner of its inaugural prize, w... | |
| The Daily Biotech Pulse: Intersect ENT J... | 07/08/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 7) AbbV... | |
| Buy rating | 02/25/21 |
| Mizuho maintains Buy rating and raises Price Target from $88.00 to $109.00 | |
| Strong Buy rating | 02/25/21 |
| Cantor Fitzgerald maintains Overweight rating and raises Price Target from $86.00 to $98.00 | |
| Strong Buy rating | 02/17/21 |
| Piper Sandler maintains Overweight rating and raises Price Target from $99.00 to $116.00 | |
| Hold rating | 01/27/21 |
| and announces Price Target of $108.00 | |
| Strong Buy rating | 12/07/20 |
| SVB Leerink maintains Outperform rating and raises Price Target from $34.00 to $58.00 | |
| Date | 2021-02-24 (AMC) | Est. (EPS/Rev.) | ($0.39)/ 4.87M |
| Actual (EPS/Rev.) | $-0.61/ $15.90 M | EPS (TTM) | 0 |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
